Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation.

AIMS Better stroke risk prediction is needed to optimize the anticoagulation decision in atrial fibrillation (AF). The ATRIA stroke risk score (ATRIA) was developed and validated in two large California community AF cohorts. We compared the performance of the ATRIA, CHADS2, and CHA2DS2-VASc scores in a national Swedish AF (SAF) cohort. METHODS AND RESULTS We examined all Swedish patients hospitalized, or visiting a hospital-based outpatient clinic, with a diagnosis of AF from July 2005 through December 2010. Variables were determined from comprehensive national databases. Risk scores were assessed via C-index (C) and net reclassification improvement (NRI). The cohort included 152 153 AF patients not receiving warfarin. Overall, 11 053 acute ischaemic strokes were observed with mean rate 3.2%/year, higher than the 2%/year in the California cohorts. Using entire point scores, ATRIA had a good C of 0.708 (0.704-0.713), significantly better than CHADS2 0.690 (0.685-0.695) or CHA2DS2-VASc 0.694 (0.690-0.700). Using published cut-points for low/moderate/high risk, C deteriorated but ATRIA remained superior. Net reclassification improvement favoured ATRIA 0.16 (0.14-0.17) vs. CHADS2 and 0.21 (0.20-0.23) vs. CHA2DS2-VASc. Net reclassification improvement decreased when cut-points were altered to better fit the cohort's stroke rates. CONCLUSION In this SAF cohort, the ATRIA score predicted ischaemic stroke risk better than CHADS2 or CHA2DS2-VASc. However, relative performance of the categorical scores varied by population stroke rates. Score cut-points may need to be optimized to better fit local population stroke rates.

[1]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[2]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[3]  Daniel E. Singer,et al.  A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score , 2013, Journal of the American Heart Association.

[4]  John Camm,et al.  Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  T. Chao,et al.  Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. , 2014, Journal of the American College of Cardiology.

[6]  W. Kremers,et al.  Concordance for Survival Time Data: Fixed and Time-Dependent Covariates and Possible Ties in Predictor and Time , 2007 .

[7]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[8]  B. Norrving,et al.  The Riks-Stroke Story: Building a Sustainable National Register for Quality Assessment of Stroke Care , 2011, International journal of stroke : official journal of the International Stroke Society.

[9]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[10]  J. Tolstrup,et al.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.

[11]  D. Singer,et al.  Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation , 2011, Circulation. Cardiovascular quality and outcomes.

[12]  L. Friberg,et al.  Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. , 2015, Journal of the American College of Cardiology.

[13]  Tjeerd P van Staa,et al.  Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. , 2015, Journal of the American College of Cardiology.

[14]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[15]  B. Dimitrov,et al.  Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke , 2011, Thrombosis and Haemostasis.

[16]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[17]  G. Lip,et al.  Stroke Risk Stratification in a “Real‐World” Elderly Anticoagulated Atrial Fibrillation Population , 2011, Journal of cardiovascular electrophysiology.

[18]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[19]  N. Cook.  Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. , 2008, Clinical chemistry.

[20]  D. Singer,et al.  Adding rigor to stroke risk prediction in atrial fibrillation. , 2015, Journal of the American College of Cardiology.

[21]  D. Singer,et al.  Death and disability from warfarin-associated intracranial and extracranial hemorrhages. , 2007, The American journal of medicine.

[22]  Mårten Rosenqvist,et al.  Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.

[23]  D. Singer,et al.  Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. , 2008, Journal of the American College of Cardiology.